Identity
FS344 is a follistatin gene-expression construct studied using a viral vector; gene delivery differs from injecting purchased protein.
Selected study only; not a complete clinical review.
Peptide library
Follistatin 344
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
The six-patient study delivered a follistatin gene using a viral vector. An uncontrolled gene-therapy result cannot validate injected commercial protein, its dose, duration or comparative safety.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
Six Becker muscular dystrophy patients; early gene-therapy study.
What the sources found
Some patients improved walking distance after vector delivery; this uncontrolled small study does not validate commercial follistatin injections.
Regulatory scope
Current authorization for the exact product and jurisdiction was not independently checked in this snapshot. A clinical trial is not marketing authorization.
What remains unknown
Selected indexed primary-study abstract reviewed. Full methods, bias, all safety outcomes, product stability, current jurisdictional authorization and a comprehensive literature search remain outstanding. This is not a complete clinical review.
How it works
FS344 is a follistatin gene-expression construct studied using a viral vector; gene delivery differs from injecting purchased protein.
The study-specific findings below distinguish biological activity from demonstrated treatment benefit.
Preclinical research
The catalog primarily cites laboratory or animal research. Human benefit, a safe dose and long-term risks cannot be inferred from those findings.
Reported adverse effects
- No adverse effects were reported in this small study; vector and protein risks are not interchangeable.
Selected study only; not a complete clinical review.
Contraindications
- A complete contraindication and interaction review remains outstanding.
Preclinical research
The catalog primarily cites laboratory or animal research. Human benefit, a safe dose and long-term risks cannot be inferred from those findings.
Sources used for this snapshot
Claim-by-claim evidence
Benefits
Some patients improved walking distance after vector delivery; this uncontrolled small study does not validate commercial follistatin injections.
Selected study only; not a complete clinical review.
Adverseeffects
No adverse effects were reported in this small study; vector and protein risks are not interchangeable.
Selected study only; not a complete clinical review.
References
A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. 2015.
PMID: 25322757
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.